StockNews.AI
INKT
StockNews.AI
106 days

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

1. MiNK Therapeutics to announce Q1 2025 results on May 15. 2. Conference call will provide strategic updates and financial insights. 3. MiNK develops innovative iNKT cell therapies for cancer treatment. 4. Company promotes scalable manufacturing for its therapies. 5. Investors should consider forward-looking statements and risks involved.

4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings release is important but does not guarantee positive results. Historical earnings reports in biotech often lead to volatility without clear direction.

How important is it?

Earnings reports are pivotal for biotech stocks, particularly affecting investor sentiment. Uncertain outcomes could sway stock performance substantially in the short run.

Why Short Term?

Next earnings report expected soon, influencing market sentiment rapidly. Short-term investor reactions could fluctuate widely based on results and forecasts.

Related Companies

AMGNBMYREGN
May 05, 2025 12:30 ET  | Source: MiNK Therapeutics NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 9822477 Webcast A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/jgzwe9ny/. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact 917-362-1370 investor@minktherapeutics.com   Media Contact 781-674-4428 communications@minktherapeutics.com   

Related News